RxDoctor Payments DataLook up a doctor →

Stanley Scheidler, DO

General Practice · Hamilton, OHNPI 1548243900

Payments from drug & device makers

$22,231in general payments, 2019–2025

Across 1,516 payments — averaging $14.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • AstraZeneca$3K
  • Astellas Pharma US Inc$1K
  • Alkermes, Inc.$1K
  • Novo Nordisk$1K
  • Amgen$1K
  • plus $12K from 54 others

What the payments were for

  • Speaking & faculty fees$6003%
  • Food & beverage$21,00394%
  • Education$6283%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)277$2,804
AstraZeneca94$2,582
Astellas Pharma US Inc58$1,212
Alkermes, Inc.27$1,147
Novo Nordisk107$1,031
Amgen(2 entities)65$1,017
Merck75$993
Bayer65$988
Otsuka America Pharmaceutical, Inc.54$780
Pfizer87$769
Grifols USA, LLC32$671
Boehringer Ingelheim27$486
Lilly USA, LLC46$486
Johnson & Johnson46$486
Supernus Pharmaceuticals, Inc.37$481
Abbott33$467
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)27$420
Novartis30$361
Takeda Pharmaceuticals U.S.A., Inc.34$331
Vanda Pharmaceuticals Inc.14$330
Sanofi-aventis U.S. LLC26$320
Exact Sciences20$288
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC16$256
GSK16$231
Sumitomo Pharma America, Inc.14$224
Amarin Pharma, Inc.22$222
Indivior Inc.20$218
Dexcom, Inc.8$207
Lundbeck LLC9$202
Gilead5$174
Antares Pharma, Inc.10$174
Mylan Specialty L.p.10$170
Xeris Pharmaceuticals, Inc.8$161
Renalytix AI, Inc.7$152
Nestle Healthcare Nutrition Inc.7$110
Scilex Pharmaceuticals Inc.7$101
Braeburn Inc.4$79
Eisai Inc.4$77
Axsome Therapeutics, Inc.3$71
MDD US Operations, LLC5$66
Tandem Diabetes Care, Inc.4$65
Daiichi Sankyo Inc.4$65
Jazz Pharmaceuticals Inc.4$63
E.r. Squibb & Sons, L.L.C.4$47
Almatica Pharma LLC2$40
Esperion Therapeutics, Inc.3$39
Kowa Pharmaceuticals America, Inc.3$37
Ironwood Pharmaceuticals, Inc3$36
Insulet Corporation2$33
Medtronic2$29
Radius Health, Inc.2$29
Verona Pharma, Inc.1$29
Shire North American Group Inc2$26
Madrigal Pharmaceuticals1$26
Hikma Pharmaceuticals USA2$26
Corcept Therapeutics1$24
IBSA Pharma Inc.1$24
Nevro Corp.1$22
Echosens North America, Inc.2$20
Phathom Pharmaceuticals, Inc.1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,231 in reported general payments places this provider in the 95th percentile of 2,933 general practice providers in Ohio.

See all general practice providers in Ohio

Medicare billing

Part B allowed, 2024
$150,217
Medicare patients
166
Services billed
5,086

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide169$198,995
MounjaroTirzepatide104$130,189
EliquisApixaban144$121,080
Trelegy ElliptaFluticasone/Umeclidin/Vilanter129$111,103
FarxigaDapagliflozin Propanediol100$91,156
OtezlaApremilast14$68,326
RexultiBrexpiprazole30$53,327
XareltoRivaroxaban51$49,348
LinzessLinaclotide53$48,883
JardianceEmpagliflozin51$41,666
VraylarCariprazine Hcl24$35,820
UbrelvyUbrogepant18$30,649
Spiriva RespimatTiotropium Bromide35$27,295
EntrestoSacubitril/Valsartan32$23,544
Breztri AerosphereBudesonide/Glycopyr/Formoterol32$22,303

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,031$213,435184 claims
Lilly USA, LLCMounjaro, Trulicity$486$149,769116 claims
GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta, Anoro Ellipta$231$133,348176 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$2,582$127,369179 claims
PfizerEliquis$769$121,080144 claims
AbbVieLinzess, Vraylar, Ubrelvy$2,804$115,35295 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat, Tradjenta$486$95,139116 claims
AmgenOtezla$1,017$68,32614 claims
Otsuka America Pharmaceutical, Inc.Rexulti$780$53,32730 claims
Johnson & JohnsonXarelto$486$49,34851 claims
MerckJanuvia, Janumet$993$35,81431 claims
NovartisEntresto$361$23,54432 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,933 general practice providers in Ohio.

Other general practice in Hamilton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →